-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
-
- Our Pipeline Development
-
Nu.Q® Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
-
Capture-Seq™
We have developed Capture-Seq™, a novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples.
Highlights from Western Veterinary Conference 2023
- Share
- Tweet
- Share on Facebook
- Share
A video highlighting Volition’s attendance at the 2023 Western Veterinary Conference, including the Nu.Q® Vet Cancer Test being available for pre-order at the point-of-care from Heska. Watch to hear from Heska’s colleagues, Volition Veterinary Chief Operating Officer, Dr. Tom Butera, Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, and various veterinarians.
Related Articles
-
Press Releases
Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
-
Press Releases
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields
